December 31, 2015 — Volpara Solutions has gone mobile with the first-ever installation of VolparaDensity in a mobile mammography unit at Saint Joseph Hospital in Denver. The VolparaDensity installation in Saint Joseph’s mobile mammography unit and their award-winning Breast Care Center, highlights the tremendous growth Volpara Solutions has experienced in 2015. VolparaDensity has been installed on more than 150 digital mammography systems in 2015, surpassing more than 500 systems at customer sites globally.
With installations recently completed at such sites as Shiela R. Veloz Breast Center, Oaklawn Hospital, Penn State Hershey Medical Center, Munson Medical Center, and many more, Volpara Solutions technology is now in use in 33 countries and more than 7 million women have had their breast density analysed using VolparaDensity.
Located in the heart of downtown Denver, the Saint Joseph Hospital Breast Care Center carries American College of Radiology (ACR) Breast Imaging Center of Excellence designation and is also part of the National Accreditation Program for Breast Centers and a U.S. Department of Health and Human Services Certified Mammography Facility. The Volpara Solutions installation at Saint Joseph Hospital provides the ability to offer objective breast density values and volumetric performance metrics for all 8,000+ mammograms performed annually on two Hologic mammography systems in the Breast Center, as well in the advanced mobile mammography system.
“At Saint Joseph Hospital we pride ourselves on a tradition of providing excellent breast health care to every patient. We’ve made a commitment to include objective, volumetric breast density assessment as our standard of care and make it available to every woman who receives her mammogram from Saint Joseph Hospital, whether it’s in the Breast Center or during one of the preventive screening events performed by our mobile mammography unit,” said Pam Heller, RT, Clinical Manager at Saint Joseph Hospital’s Breast Care Center. “The addition of VolparaDensity enables us to thoroughly and accurately measure breast density for every woman we serve, improving our ability to detect breast cancer as early as possible.”
Cleared by the FDA, HealthCanada, the TGA and CE-marked, VolparaDensity is in use at breast imaging centers worldwide to help radiologists objectively assess density from both digital mammography and tomosynthesis data and to determine which women would benefit from additional screening. Highly correlated to breast MR assessments, VolparaDensity is a reliable tool that automatically generates an objective measurement of volumetric breast density correlated to the fourth and fifth Editions of the Breast Imaging-Reporting and Data System (BI-RADS) Atlas from the American College of Radiology (ACR). VolparaDensity is part of a suite of quantitative breast imaging tools built on the Volpara Solutions algorithm that allows for personalized measurements of density, patient dose, breast compression and other factors designed to help maintain accuracy and consistent quality in breast screening.
“With extensive validation of the ability of volumetric breast density assessment to help overcome the limitations of mammography, combined with pivotal research demonstrating a strong link between breast cancer risk and density, we have seen significant adoption of VolparaDensity and our suite of quantitative breast imaging solutions,” said Ralph Highnam, Ph.D., CEO and chief scientist, Volpara Solutions. “With tremendous direct customer relationships and partnerships with key OEM partners like Siemens, GE Healthcare and Gamma Medica, not only have we experienced strong growth this year, but we have also generated a strong order pipeline going coming out of RSNA and into next year.”
For more information: www.SaintJosephDenver.org, www.volparasolutions.com
November 29, 2025 
